Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marwan Sabbagh

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
BMC Geriatrics|June 8, 2013
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment responseMarwan Sabbagh, Jeffrey Cummings, Daniel Christensen, et al.
Journal of Alzheimer'S Disease : JAD|January 25, 2005
Is there a characteristic lipid profile in Alzheimer's disease?Marwan Sabbagh, H Reza Zahiri, Joanne Ceimo, et al.
Neurology and Therapy|July 9, 2026
Defining and Measuring Cognitive Decline and Clinical RelevanceCarolin Kurz, Paul Newhouse, Kate A Wyman-Chick, et al.
BMC Neurology|January 16, 2014
Effect of TTP488 in patients with mild to moderate Alzheimer's diseaseAaron H Burstein, Imogene Grimes, Douglas R Galasko, et al.
Journal of Rehabilitation Research and Development|May 6, 2017
Sensor-based balance training with motion feedback in people with mild cognitive impairmentMichael Schwenk, Marwan Sabbagh, Ivy Lin, et al.
Alzheimer'S Research & Therapy|February 26, 2013
Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severitySteven Ferris, Jeffrey Cummings, Daniel Christensen, et al.
The Journal of Prevention of Alzheimer'S Disease|April 26, 2025
Brain photobiomodulation: a potential treatment in Alzheimer's and Parkinson's diseasesGuillaume Blivet, Benjamin Touchon, Hugo Cavadore, et al.
Current Alzheimer Research|December 27, 2005
Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT)D Larry Sparks, Suzana Petanceska, Marwan Sabbagh, et al.
The International Journal of Neuroscience|February 5, 2010
Olfaction in the elderly: a cross-sectional analysis comparing Parkinson's disease with controls and other disordersJonathan McKinnon, Virgilio Evidente, Erika Driver-Dunckley, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 23, 2023
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's diseaseLawrence S Honig, Jerome Barakos, Shobha Dhadda, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
BMC Geriatrics|June 8, 2013
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment responseMarwan Sabbagh, Jeffrey Cummings, Daniel Christensen, et al.
Journal of Alzheimer'S Disease : JAD|January 25, 2005
Is there a characteristic lipid profile in Alzheimer's disease?Marwan Sabbagh, H Reza Zahiri, Joanne Ceimo, et al.
Neurology and Therapy|July 9, 2026
Defining and Measuring Cognitive Decline and Clinical RelevanceCarolin Kurz, Paul Newhouse, Kate A Wyman-Chick, et al.
BMC Neurology|January 16, 2014
Effect of TTP488 in patients with mild to moderate Alzheimer's diseaseAaron H Burstein, Imogene Grimes, Douglas R Galasko, et al.
Journal of Rehabilitation Research and Development|May 6, 2017
Sensor-based balance training with motion feedback in people with mild cognitive impairmentMichael Schwenk, Marwan Sabbagh, Ivy Lin, et al.
Alzheimer'S Research & Therapy|February 26, 2013
Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severitySteven Ferris, Jeffrey Cummings, Daniel Christensen, et al.
The Journal of Prevention of Alzheimer'S Disease|April 26, 2025
Brain photobiomodulation: a potential treatment in Alzheimer's and Parkinson's diseasesGuillaume Blivet, Benjamin Touchon, Hugo Cavadore, et al.
Current Alzheimer Research|December 27, 2005
Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT)D Larry Sparks, Suzana Petanceska, Marwan Sabbagh, et al.
The International Journal of Neuroscience|February 5, 2010
Olfaction in the elderly: a cross-sectional analysis comparing Parkinson's disease with controls and other disordersJonathan McKinnon, Virgilio Evidente, Erika Driver-Dunckley, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 23, 2023
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's diseaseLawrence S Honig, Jerome Barakos, Shobha Dhadda, et al.
Pageof 10